Lilly obesity pill Foundayo projected to earn billions

Wall Street analysts are forecasting a multi-billion dollar debut for the newly approved weight-loss pill from ELI LILLY & CO, as the company moves to challenge the early market lead held by NOVO NORDISK A/S-B. The drug, known chemically as orforglipron and branded as Foundayo, is expected to generate significant revenue as early as this year. Brokerages have provided a wide range of estimates for 2026 sales, spanning from $1.5 billion to $2.8 billion, reflecting both high expectations for patient demand and the inherent uncertainties of a major pharmaceutical launch. Among the most optimistic voices on Wall Street, Citi analysts project that Foundayo could achieve $2.8 billion in revenue by 2026, with peak annual sales eventually surpassing $40 billion. Bernstein offers a similarly bullish outlook, estimating the drug will generate between $2 billion and $2.5 billion in its first full year of availability. More conservative figures from Guggenheim Partners place 2026 revenue at approximately $1.5 billion. Despite these variations, the consensus remains that the pill will fundamentally alter the competitive landscape for obesity treatments. The emergence of a robust oral medication class is further supported by UBS, which estimates that the combined sales of Lilly’s drug and the oral version of Wegovy from Novo Nordisk will reach $5 billion by 2026. Analysts at J.P. Morgan suggest that Foundayo’s advantages in manufacturing scalability and fewer dosing restrictions could propel it to become the leading oral option globally, with sales potentially surging to $6 billion by 2027. While the long-term outlook is strong, Bernstein analysts cautioned that early revenue might be affected by launch dynamics such as free sampling, lower initial dosing, and strategic pricing adjustments. Market observers will be paying close attention to weekly new-patient starts as a primary indicator of the drug's commercial trajectory. Currently, Novo Nordisk benefits from a first-mover advantage and established brand recognition, which has helped it secure early adopters. Looking toward the next decade, the impact of oral treatments is expected to be transformative. Morningstar estimates that obesity pills could represent roughly one-third of a projected $180 billion global market for weight-loss therapies by 2034. This shift highlights the growing preference for convenient oral alternatives over traditional injectable treatments.